Endo International PLC (ENDP)

11.47
0.12 1.10
NASDAQ : Health Care
Prev Close 11.35
Open 11.42
Day Low/High 11.22 / 11.49
52 Wk Low/High 12.56 / 88.54
Volume 1.67M
Avg Volume 6.95M
Exchange NASDAQ
Shares Outstanding 223.11M
Market Cap 2.63B
EPS -15.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Opioid Marketing Under Bipartisan Investigation

Opioid Marketing Under Bipartisan Investigation

Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors Of The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Endo International Plc -- ENDP

Levi & Korsinsky announces it has commenced an investigation of Endo International plc (NASDAQ: ENDP) concerning possible violations of federal securities laws.

Arons & Arons, LLC. Announces Investigation On Behalf Of Endo International Plc Investors

The Law Firm of Arons & Arons, LLC. has initiated an investigation of Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP) on behalf of the company's investors for possible violations of federal securities...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Endo International Plc

Levi & Korsinsky announces it has commenced an investigation of Endo International plc (NASDAQ:ENDP) concerning possible violations of federal securities laws.

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Endo International Plc Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Endo International plc ("Endo" or the "Company") (NASDAQ: ENDP) concerning the Company and its officers' possible violations of federal...

Endo Shares Down as FDA Seeks Removal of Opioid Pain Medication

Endo Shares Down as FDA Seeks Removal of Opioid Pain Medication

This marks the first time that the FDA is seeking to remove an opioid pain medication from the market due to the public health consequences of abuse.

Uber's Quarterly Loss was a Staggering $708 Million, Key Exec Leaves

Uber's Quarterly Loss was a Staggering $708 Million, Key Exec Leaves

Uber's first quarter loss was less than the $991 million loss reported 3 months ago.

Ohio Going After Drug Makers for Fueling Opioid Crisis

Ohio Going After Drug Makers for Fueling Opioid Crisis

Ohio Attorney General Mike DeWine claims the companies weren't honest with doctors about the risks associated with the painkillers.

3 Small Biotech Value Plays

3 Small Biotech Value Plays

These stocks will be great stories in the second half of 2017, and are significantly undervalued.

These Stocks Show Change of Direction

These Stocks Show Change of Direction

Finding bullish and bearish reversals in the market.

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.

Perrigo Stock Sliding on DOJ Search

Perrigo Stock Sliding on DOJ Search

The investigation is in relation to drug pricing in the pharmaceutical industry.

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.

Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers

Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers

Biogen's new spine disease drug outperformed expectations during its commercial debut.

Biotech Movers: Organovo, Endo, Omeros

Biotech Movers: Organovo, Endo, Omeros

Organovo, Endo and Omeros were among the biotech stock moves in premarket trading on Thursday.

Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data

Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data

Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.

Endo international, AngioDynamics Lead Biotech Movers

Endo international, AngioDynamics Lead Biotech Movers

Endo International slipped 5% ahead of market's open Friday.

FDA deals blow to Endo over Opana ER Pain Med

FDA deals blow to Endo over Opana ER Pain Med

An FDA advisory committee has found that risks of Endo International's pain drug Opana ER now overshadow the drug's benefits.